WASHINGTON, Feb. 3, 2026 /PRNewswire/ — Glencore and the Orion Critical Mineral Consortium (“Orion CMC”) announce that they have entered into a non-binding Memorandum of Understanding in relation to a potential acquisition by Orion CMC of a 40% stake in Glencore’s interests in its Democratic Republic of Congo (“DRC”) assets, Mutanda Mining (“Mumi”) and Kamoto Copper Company (“KCC”). The transaction is expected to imply a combined enterprise value for Mumi and KCC of around $9 billion.

Orion CMC will have the right to appoint non-executive directors in respect of the assets and direct the sale of the relevant share of production from the assets to nominated buyers, in accordance with the U.S.-DRC Strategic Partnership Agreement, thereby securing critical minerals for the United States and its partners. Mumi and KCC would continue to be managed as part of the Glencore Group.

Glencore and Orion CMC will also look for opportunities to expand and develop Mumi and KCC, working with the DRC Government and Gécamines, Glencore’s existing partner in KCC, as well as to acquire additional critical mineral projects and assets in the DRC and the African copper belt more broadly.

Established in October 2025 and led by Orion Resource Partners in partnership with the U.S. government, Orion CMC is a mission-driven consortium designed to support the United States and its allied and partner nations to develop secure, responsible, and resilient supply chains for the critical minerals that underpin future economic growth and security. 

The proposed transaction remains subject to due diligence, the execution of legally binding documentation and any applicable regulatory approvals. 

U.S. Deputy Secretary of State Christopher Landau, said: “The United States government is fully committed to the Washington Accords and ensuring peace, stability and prosperity throughout the entire Great Lakes region. This proposed transaction between Glencore and the US-backed Orion Critical Mineral Consortium reflects the core objectives of the U.S.-DRC Strategic Partnership Agreement by encouraging greater U.S. investment in the DRC’s mining sector and promoting secure, reliable, and mutually beneficial flows of critical minerals between our two countries. We look forward to continued close engagement with the DRC government to advance this transaction in a manner that delivers benefits for both our peoples and sets a positive example for future U.S. investment.”

DFC CEO Ben Black, said “This proposed partnership between Orion CMC and Glencore has the potential to bring significant returns for both the United States and the DRC. CMC’s potential investment would reflect the growing relationship between the U.S. and the DRC, help secure a reliable source of critical minerals for the United States and our partners, and drive economic opportunity and regional stability for the DRC.”

Gary Nagle, CEO of Glencore, said: “We are pleased that the U.S. Government and Orion CMC have recognized Glencore’s role as the only major Western producer of copper and cobalt in the DRC, through our high-quality assets, Mumi and KCC.  Through this partnership, we would be able to support the ambitions of the U.S. Government and private sector with the supply of two critical minerals.”

“The proposed transaction also represents a significant vote of confidence in the DRC Government’s ongoing efforts to attract major foreign investment to the country and further develop its mining industry. As the world’s largest producer of cobalt and one of the largest copper producers, the DRC plays a vital role in supporting the technology, defense and critical infrastructure roll-out of today and the future.”

Oskar Lewnowski, Founder and Chief Executive Officer of Orion Resource Partners LP, said: “This proposed transaction is exactly what Orion CMC was established to achieve – securing long-life, high-quality production of critical minerals while supporting resilient supply chains for the United States and its allies. It underscores both the scale of the opportunity and the strategic importance of the Consortium’s mission, and this partnership will create a strong platform from which Orion CMC can further develop critical mineral assets and pursue additional investment opportunities. We look forward to working closely with Glencore and the U.S. DFC to advance these shared ambitions.”

About Glencore

Glencore is one of the world’s largest global diversified natural resource companies and a major producer and marketer of more than 60 commodities that advance everyday life. Through a network of assets, customers and suppliers that spans the globe, we produce, process, recycle, source, market and distribute the commodities that advance everyday life.

KCC’s operations produce copper and cobalt hydroxide from its two open pit mines and one underground mine and Mumi’s operations produce copper and cobalt from its three open pit mines, providing raw ore feed for our copper and cobalt production facilities. In 2025, KCC and Mumi produced a combined 247.8kt copper metal and 33.5 kt cobalt contained in concentrates and hydroxides. In 2025, both KCC and Mumi achieved The Copper Mark, after comprehensive self and independent assessments to evaluate the sites’ alignment with 33 globally recognized criteria on responsible mining. 

About Orion CMC

Orion CMC is an investment consortium led by Orion Resource Partners LP, and includes the U.S. International Development Finance Corporation (DFC). Orion CMC represents one of the largest initiatives aimed at creating secure supply chains for critical minerals to the United States and its allies.    

About Orion Resource Partners

Orion Resource Partners LP is a global investment firm specializing in the metals and materials critical to sustainable economic growth and energy transition, with more than $8 billion of assets under management and a team of more than 80 professionals across five global offices. Orion has successfully invested across the metals and materials value chain for over a decade, operating complementary investment strategies spanning the full liquidity spectrum, finding and capturing opportunities driven by the long-term trends of global decarbonization, the constrained supply of critical resources, and advancements in industrial technologies. Orion is a signatory to the UN PRI and the IFC Performance Standards on Environmental and Social Sustainability. For more information visit www.orionrp.com

Greenbrook
Peter Hewer, Cecilie Oerting
Email: orionresourcepartners@greenbrookadvisory.com 
Tel: +44 (0) 20 7952-2000

HONG KONG, Feb. 3, 2026 /PRNewswire/ — On January 15, Qingdao Guoen Technology Co., Ltd. (SHE: 002768) announced that it has successfully passed the hearing of the Hong Kong Stock Exchange (HKEX) Main Board, marking a significant milestone in its pursuit of a dual listing on both the Shenzhen and Hong Kong stock exchanges. The company’s H-share initial public offering (IPO) will be exclusively sponsored by China Merchants Securities International.

According to the updated prospectus and official announcement dated February 3, Guoen Technology has finalized the issue price of its H-shares at HK$36.00 per share, excluding relevant fees. A total of 30 million shares will be offered globally—3 million for the Hong Kong public offering and 27 million for international placement, with an over-allotment (greenshoe) option available. The Hong Kong public offering period ran from January 27 to January 30. Trading of the H-shares is scheduled to commence on February 4, 2026, on the HKEX Main Board.

This IPO is expected to raise capital primarily for the development of domestic and overseas manufacturing bases, as well as to supplement working capital—supporting the company’s long-term goal of building a cross-market, globally integrated supply platform.

Founded in Qingdao, Guoen Technology is a leading player in the advanced polymer materials sector. The company operates a vertically integrated platform covering the entire value chain of high-performance plastics—from raw material polymerization to modification, compounding, and the manufacturing of end-use products. Its product portfolio spans modified plastics, composite materials, and biodegradable polymers, with strong applications in sectors such as new energy vehicles, smart manufacturing, consumer electronics, and healthcare.

Notably, Guoen is accelerating investment into strategic materials such as PEEK (polyether ether ketone), a high-performance engineering thermoplastic widely used in aerospace, medical devices, and robotics. The company has announced plans to establish 1,000-ton annual PEEK production capacity, positioning itself at the forefront of domestic innovation and import substitution in this field.

This is a critical step for Guoen Technology to deepen capital market access, enhance international brand recognition, and advance its ambition to become a global materials technology platform.

Company delivers more than 100 kilometers to one of its customers and accelerates toward gigawatt-hour scale manufacturing

SANTA CLARA, Calif., Feb. 3, 2026 /PRNewswire/ — Elevated Materials today announced major milestones as it celebrates its one-year anniversary, highlighting rapid growth in production, customer adoption, and organizational scale. Elevated Materials was carved out of Applied Materials on February 1, 2025, with an investment from the TPG Rise Climate Fund.

The company closed 2025 with record output of ultra-thin lithium metal films, shipping product to more than 30 customers worldwide. Notably, Elevated Materials delivered more than 100 kilometers of lithium film to a single customer, underscoring strong market demand for high-quality, scalable lithium metal solutions.

“The industry has long been seeking a reliable source of high-quality, ultra-thin lithium films to improve battery performance,” said Jim Cushing, CEO of Elevated Materials. “We are filling that gap with our ultra-thin, smooth, and low-defect ELi™ films. Demand has been particularly strong for lithium metal anodes, where ELi significantly improves both safety and performance.”

Elevated Materials’ proprietary roll-to-roll vacuum deposition platforms produce ELi, the industry’s highest-quality ultra-thin lithium metal films. These films enable next-generation anode architectures across electric vehicles, consumer electronics, aviation, and grid-scale energy storage.

The company’s production momentum reflects the growing urgency among battery manufacturers to secure reliable supplies of ultra-thin lithium metal anodes as advanced cell designs move closer to commercial deployment.

Looking ahead, Elevated Materials noted that 2026 will be focused on scaling production to meet increasing customer demand.

“As we move into 2026, Elevated Materials will continue ramping to true gigawatt-hour scale manufacturing,” Cushing added. “With accelerating customer demand, we are tripling production capacity to support the commercial battery programs of our key customers.”

Elevated Materials’ successful first year and rapid scale-up reinforce its position as a critical supplier for next-generation battery developers seeking consistent, scalable lithium metal solutions.

About Elevated Materials
Elevated Materials is a TPG Rise Climate portfolio company carved out of Applied Materials and focused on scaling breakthrough battery technologies to accelerate global decarbonization and electrification. The company draws on decades of expertise in semiconductors and roll-to-roll vacuum deposition to deliver the industry’s widest and highest-quality ultra-thin lithium films. Elevated’s films boost energy density, extend battery life, and enable significantly faster charging across lithium-ion battery applications and anode chemistries.

HONG KONG, Feb. 3, 2026 /PRNewswire/ — CIMG Inc. (“CIMG” or the “Company”) (Nasdaq: IMG), a business group specializing in digital health and sales development, which utilizes technologies and marketing networks to enhance its business partners’ sales growth and commercial value, today announced that its subsidiary, Beijing Xinmiao Shidai Technology Development Co., Ltd. has entered into five sales contracts for computing power hardware equipment with multiple companies, including Guangzhou Liangjingjing Technology Co., Ltd., Tianjin Herunsheng Technology Development Co., Ltd., Tianjin Weixinda Technology Co., Ltd., and Tianjin Lanhai Interaction Technology Co., Ltd., which contracts were executed between December 2025 and January 2026. The total contract value, including taxes, amounts to approximately $2 million.

The products covered by these contracts include two main categories, computing servers and power electronic components, and are intended for customers such as cloud service providers and industrial enterprises. These contracts reflect the Company’s continued expansion in the core hardware segment of the computing power infrastructure industry and are expected to contribute to the Company’s financial performance and operating results in 2026.

Alice Wang, Chairperson of the Board and Chief Executive Officer of CIMG Inc., stated, “With the industrial deployment of large-scale models and the deepening of the China ‘East Data West Computing; strategy, computing power has evolved from a basic resource into a strategic asset comparable to semiconductors and energy. Our continued focus on the artificial intelligence computing power sector is intended to support long-term customer resources and strengthen our competitive positioning.”

“Currently, the Company is focused on developing ‘scenario-based computing power solutions.’ To address the varying technical needs and budget constraints of different clients, the Company provides end-to-end services, including hardware configuration, equipment installation and debugging, optimization and after-sales support, aimed at addressing compatibility issues in traditional computing power procurement. The Company expects to continue expanding its business in the computing power facility services sector, leveraging innovative business models to capture opportunities arising from the global AI industry development,” added Alice Wang.

About CIMG

CIMG is a business group specializing in digital health and sales development, with a cryptocurrency-focused strategy. The Company leverages AI and cryptocurrencies (such as Bitcoin and stablecoins) to drive business growth, helping clients maximize user growth and enhance brand management value. The Company’s current client portfolio includes brands such as Kangduoyuan, Maca-Noni, Qianmao, Huomao, and Coco-mango.

Forward-Looking Statements

This press release contains information about the Company’s view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks related to the execution, timing, and realization of supply and sales contracts, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary for its operations, and its ability to protect its intellectual property. The Company encourages you to review other factors that may affect its future results in its Annual Reports, Quarterly Reports, registration statements, and other filings with the Securities and Exchange Commission.

Followed by the development and regulatory milestone payment of USD 3 million in July 2025, Insilico received an additional milestone payment of USD 5 million from Menarini Group after first-in-patient dosing in a Phase 1 trial of MEN2501, highly differentiated small molecule KIF18A inhibitor in development for chromosomally unstable solid tumors designed using Insilico’s generative AI engine.

CAMBRIDGE, Mass., Feb. 3, 2026 /PRNewswire/ — Insilico Medicine (“Insilico”), a clinical-stage, generative artificial intelligence (AI)-driven biotechnology company, today announced that it has received USD 5 million from Menarini Group (“Menarini”) as an additional milestone payment, following the completion of first-in-patient dosing in a Phase 1 study of MEN2501, which was licensed to Menarini in January 2025. MEN2501 (previously known as ISM9682) is a highly differentiated small molecule inhibitor of kinesin KIF18A motor protein with potent activity in cancers with chromosome instability.  

As part of a strategic collaboration to accelerate the development and delivery of transformative cancer therapies, the asset was subsequently licensed to Stemline Therapeutics, Inc. (“Stemline”), a wholly owned subsidiary of the Menarini Group, with the combined value of the agreements exceeding USD 550 million. Pursuant to the partnership, both parties actively advanced the program transition and subsequent development activities. Following IND approval for this program, Insilico received the first development and regulatory milestone payment of USD 3 million in July 2025.

“The program rapidly advanced into a Phase I clinical trial and successfully completed first patient dosing, fully demonstrating Menarini and Stemline’s exceptional agility and clinical expertise,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. “This milestone shows our shared commitment to delivering innovative therapies for cancer treatment. We are proud to further strengthen our partnership and encouraged to see AI-discovered drug candidates reaching such a critical stage, bringing us closer to providing novel treatment options for patients worldwide.”

“Getting the first patient dosed in our MEN2501 Phase 1 study is a meaningful milestone that underscores how quickly promising science can move forward through focused clinical execution,” said Elcin Barker Ergun, CEO of the Menarini Group. “We value our partnership with Insilico as we translate AI-enabled discovery into clinical programs, with the goal of bringing new, transformational treatment options to patients facing aggressive cancers.”

The collaboration between Insilico and Menarini has continued to expand since its inception. Prior to MEN2501, in January 2024, Insilico announced that it entered into an exclusive global license collaboration with Menarini for MEN2312, a novel KAT6 inhibitor for breast cancer and other oncology indications, with the combined value of the agreements exceeding USD 500 million. The MEN2312 program has progressed smoothly into clinical development, and Insilico has received early development milestone payments.

In addition to the collaboration pipelines, Insilico has extensive experience in AI-driven oncology, drug discovery and development. The company has established a robust oncology pipeline that targets multiple cancer indications, leveraging both moderately novel and well-established mechanisms. Among its most promising assets, the potential best-in-class pan-TEAD inhibitor ISM6331 and the MAT2A inhibitor ISM3412 are both undergoing global, multicenter Phase I clinical trials.

Harnessing state-of-the-art AI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development, setting a benchmark for AI-driven drug R&D. While traditional early-stage drug discovery typically requires an average of 4.5 years, Insilico has nominated 20 preclinical candidates from 2021 to 2024, with an average timeline—from project initiation to preclinical candidate (PCC) nomination—of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program. 

About Insilico Medicine 

Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.

By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com